Drugs / ABBV-176
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03145909 | Jul 2017 → Nov 2018 | — | AbbVie | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03145909 ↗ |
| Action | Deplete | “conjugated to a highly potent, cytotoxic cross-linking pyrrolobenzodiazepine dimer (PBD; SGD-1882) targeting the prolactin receptor (PRLR)” PMID 32524319 ↗ Jun 2020 |
| Modality | Other / unclassified | “ABBV-176 is an antibody-drug conjugate composed of the humanized antibody h16f (PR-1594804) conjugated to a highly potent, cytotoxic cross-linking pyrrolobenzodiazepine dimer...” PMID 32524319 ↗ Jun 2020 |
| Route | Intravenous | “Intravenous infusion” NCT03145909 ↗ |